Lipocine (NASDAQ:LPCN) & Harmony Biosciences (NASDAQ:HRMY) Head-To-Head Analysis

Harmony Biosciences (NASDAQ:HRMY) and Lipocine (NASDAQ:LPCN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Profitability

This table compares Harmony Biosciences and Lipocine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
Lipocine	-755.39%	-64.75%	-57.62%

Insider and Institutional Ownership

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 4.7% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Harmony Biosciences and Lipocine”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45 million	2.48	$158.69 million	$3.08	12.02
Lipocine	$1.98 million	6.74	-$9.63 million	($1.79)	-0.91

Harmony Biosciences has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Harmony Biosciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Harmony Biosciences and Lipocine, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1	4	6	0	2.45
Lipocine	1	1	1	0	2.00

Harmony Biosciences presently has a consensus price target of $47.44, suggesting a potential upside of 28.12%. Lipocine has a consensus price target of $4.00, suggesting a potential upside of 146.91%. Given Lipocine’s higher probable upside, analysts plainly believe Lipocine is more favorable than Harmony Biosciences.

Summary

Harmony Biosciences beats Lipocine on 11 of the 13 factors compared between the two stocks.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

About Lipocine

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.